share_log

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

諾瓦瓦克斯醫藥 | S-8：員工福利計劃證券登記
美股SEC公告 ·  08/08 16:21
Moomoo AI 已提取核心訊息
On August 8, 2024, Novavax, Inc., a biotechnology company incorporated in Delaware and headquartered in Gaithersburg, Maryland, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This registration statement pertains to the issuance of additional shares under the company's employee benefit plans. Specifically, Novavax registered 1,810,264 additional shares of common stock for its Amended and Restated 2013 Employee Stock Purchase Plan and 6,500,000 additional shares for its Amended and Restated 2015 Stock Incentive Plan. The filing includes references to previous registration statements and incorporates by reference several of Novavax's financial documents, including annual and quarterly reports, as well as current reports and proxy statements. The registration statement also details the company's indemnification policies for directors and officers, and includes a list of exhibits related to the company's corporate governance documents.
On August 8, 2024, Novavax, Inc., a biotechnology company incorporated in Delaware and headquartered in Gaithersburg, Maryland, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This registration statement pertains to the issuance of additional shares under the company's employee benefit plans. Specifically, Novavax registered 1,810,264 additional shares of common stock for its Amended and Restated 2013 Employee Stock Purchase Plan and 6,500,000 additional shares for its Amended and Restated 2015 Stock Incentive Plan. The filing includes references to previous registration statements and incorporates by reference several of Novavax's financial documents, including annual and quarterly reports, as well as current reports and proxy statements. The registration statement also details the company's indemnification policies for directors and officers, and includes a list of exhibits related to the company's corporate governance documents.
2024年8月8日，總部位於馬里蘭蓋瑟斯堡的生物技術公司諾瓦瓦克斯醫藥在特拉華州註冊，向證券交易委員會（SEC）提交了S-8表格的註冊聲明。該註冊聲明涉及該公司在僱員福利計劃下發行額外股份的事宜。具體而言，諾瓦瓦克斯醫藥爲其2013年修訂版員工股票購買計劃註冊了1810264股普通股和6500000股修訂版2015股權激勵計劃的額外股份。此次提交包含有關以往登記聲明的參考文獻，並參照了諾瓦瓦克斯醫藥的若干財務文件，包括年度和季度報告，以及目前的報告和代理聲明。註冊聲明還詳細說明了公司董事和高管的賠償政策，並列出了與公司公司治理文件相關的展品清單。
2024年8月8日，總部位於馬里蘭蓋瑟斯堡的生物技術公司諾瓦瓦克斯醫藥在特拉華州註冊，向證券交易委員會（SEC）提交了S-8表格的註冊聲明。該註冊聲明涉及該公司在僱員福利計劃下發行額外股份的事宜。具體而言，諾瓦瓦克斯醫藥爲其2013年修訂版員工股票購買計劃註冊了1810264股普通股和6500000股修訂版2015股權激勵計劃的額外股份。此次提交包含有關以往登記聲明的參考文獻，並參照了諾瓦瓦克斯醫藥的若干財務文件，包括年度和季度報告，以及目前的報告和代理聲明。註冊聲明還詳細說明了公司董事和高管的賠償政策，並列出了與公司公司治理文件相關的展品清單。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息